Preclinical double-humanized CTLA-4/LAG3 mouse model

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Applications & Features
Resources
Validation Data

Applications of the hCTLA-4/hLAG3 mouse model

Useful applications for researchers working on different biomedical fields, such as immuno-oncology and autoimmunity:

Assess the efficacy of CTLA-4 and/or LAG3-targeting therapeutics
- Perform tumor growth inhibition assays in the context of monotherapies or combotherapies
Investigate the mode of action (MoA) of CTLA-4 and/or LAG3-targeting compounds and understand their therapeutic potential

Features

Physiological regulation and expression pattern of the human CTLA-4 and human LAG3
Expression of different hCTLA-4 isoforms
Fully functional mouse immune system
Lack of expression of the murine target genes

Clients

No items found.

Related resources and publications

pulmonary embolism (PE)

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

nutrition

pain research

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

BRGSF-HIS & hVISTA for immunotherapies

Nov 2022

No results

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read

Jun 2023

A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read

Jul 2022

An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

4 min read

Mar 2022

Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

5 min read

Mar 2022

Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

3 min read

Apr 2021

Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies

Immuno-oncolology models

15 min read

May 2020

A VISTA on naive T cell fate

Humanized ICP mouse

3 min read

Feb 2020

A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

3 min read

Oct 2019

Immune checkpoint inhibitors: A strategy to tackle cancer?

Immuno-oncology models (ICP)

3 min read

Jul 2019

Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

5 min read

Apr 2021

Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Bispecific antibodies

5 min read

Apr 2021

No results

Validation data

hCTLA‑4 expression pattern in hCTLA-4/hLAG3 mice recapitulates mCTLA-4 in wild-type mice
Splenocytes from hCTLA-4/hLAG3 double-homozygous mice were activated with coated αCD3/αCD28 and mIL-2 for 2 days (A, B) or indicated time (C,D). hCTLA-4 and mCTLA-4 expressions were evaluated on A) Tregs (viable, CD3⁺CD4⁺CD25⁺Foxp3⁺), B) conventional CD4⁺ (viable, CD3⁺CD4⁺Foxp3^-), and C, D) CD8⁺ (viable, CD3⁺CD8⁺) T cells.
hLAG3 expression pattern in hCTLA‑4/hLAG3 double-humanized model
Splenocytes from wild-type or hCTLA-4/hLAG3 double-homozygous mice were activated with coated αCD3/αCD28 and mIL-2 for 2 days (A, B) or indicated time (C, D). hLAG3 and mLAG3 expression on A) Tregs (viable, CD3⁺CD4⁺CD25⁺Foxp3⁺), B) conventional CD4⁺ (viable, CD3⁺CD4⁺Foxp3^-), and C, D) CD8⁺ (viable, CD3⁺CD8⁺) T cells.

Discover related products to

hCTLA-4/hLAG3

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Immune checkpoint

PD-1

GITR

ICP (multi-target)

GITRL

genO-hPD-1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint

CD39

ICP (single-target)

genO‑hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint

OX40

ICP (single-target)

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint

VISTA

ICP (single-target)

genO‑hVISTA

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Immune checkpoint

CD28

ICP (single-target)

T-cell engager

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint

CTLA-4

ICP (single-target)

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Preclinical double-humanized CTLA-4/LAG3 mouse model

Get in touch about

Let us know how we can help

New humanized

FcγR mouse

Needs

Science

Company

Preclinical double-humanized CTLA-4/LAG3 mouse model

Applications of the hCTLA-4/hLAG3 mouse model

Features

Clients

Related resources and publications

Validation data

hCTLA‑4 expression pattern in hCTLA-4/hLAG3 mice recapitulates mCTLA-4 in wild-type mice

hLAG3 expression pattern in hCTLA‑4/hLAG3 double-humanized model

Discover related products to

hCTLA-4/hLAG3

genO-hPD-1/hGITR/hGITRL

genO‑hCD39

genO‑hOX40

genO‑hPD-1

genO‑hPD-1/hPD-L1

genO‑hPD‑1/hLAG3

genO‑hVISTA

hCD28

hCTLA-4

hGITR

hGITR/hGITRL

hPD-1/hCTLA-4

hPD-1/hTIM3

hPD-1/hVISTA

Preclinical double-humanized CTLA-4/LAG3 mouse model

Get in touch about

Scientific excellence

Robust validation data on catalog models

Customer care

Easy and fast access to models